Investors
Corporate Profile
Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions. From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes.
Our DecisionDx tests provide personalized, clinically actionable information to help healthcare providers and patients make more informed decisions about their treatment plans. Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile, or GEP, test that more accurately predicts a patient’s risk of metastasis or recurrence as well as sentinel lymph node positivity. DecisionDx®-SCC is our GEP test that predicts the risk of metastasis for patients with cutaneous squamous cell carcinoma who have one or more risk factors. DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Our newest proprietary gene expression profile test, DecisionDx® DiffDx™-Melanoma is designed to provide a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions.
We entered 2020 with a U.S. total addressable market (TAM) of $540 million. Following the successful validation and commercial launch of our two pipeline tests, DecisionDx-SCC and DecisionDx DiffDx-Melanoma, we exited 2020 with an estimated in-market U.S. TAM of $2.0 billion. We have initiated additional research and development programs for tests in other dermatologic diseases with high clinical need which, if successful, will add additional, significant U.S. TAM.
Latest Quarterly Earnings
Recent News
-
Feb 22, 2021
-
Feb 8, 2021
Castle Biosciences to Present at Upcoming Investor Conferences
-
Feb 4, 2021
Recent Events
-
Mar 8, 2021 at 4:30 PM EST
Castle Biosciences Q4 2020 Earnings Call
Listen to Webcast Link to Castle Biosciences Q4 2020 Earnings Call webcast -
Feb 24, 2021 at 10:00 AM EST
10th Annual SVB Leerink Global Healthcare Conference
Listen to Webcast Link to 10th Annual SVB Leerink Global Healthcare Conference webcast -
Feb 17, 2021 at 10:30 AM EST
BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
View The Live Webcast Link to BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference webcast